


Claims

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, where:

R¹ is methyl;

R² is hydro or methyl; or **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring;

R³ is hydro or fluoro;

R⁴ is hydro or methyl; and

R⁵ is hydro or fluoro.

2. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where **R¹** and **R²** are both methyl; or **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring.
3. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or claim 2, where **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring.
4. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of the preceding claims, where **R³** is hydro.
5. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of the preceding claims, where **R⁴** is methyl.

6. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof as claimed in any one of the preceding claims, where **R⁵** is fluoro.
- 5 7. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where:
- R¹** is methyl;
- R²** is methyl; or **R¹** and **R²** together with the nitrogen atom to which they are bonded form an azetidiny, pyrrolidiny or piperidiny ring;
- 10 **R³** is hydro or fluoro;
- R⁴** is methyl; and
- R⁵** is hydro or fluoro.
8. The compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, where the compound is selected from the group consisting of:
- 15 8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;
- 7-Fluoro-1-isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one;
- 20 7-Fluoro-1-isopropyl-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-c]quinolin-2-one;
- 8-[6-[3-(azetidin-1-yl)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;
- 1-Isopropyl-3-methyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]imidazo[4,5-c]quinolin-2-one;
- 25 8-[6-[3-(dimethylamino)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;
- 1-isopropyl-3-methyl-8-[6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]imidazo[4,5-c]quinolin-2-one;
- 30 8-[6-[3-(Azetidin-1-yl)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[2-Fluoro-6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(dimethylamino)propoxy]-2-fluoro-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

5 8-[6-[3-(dimethylamino)propoxy]-2-fluoro-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[2-fluoro-6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

10 7-fluoro-8-[2-fluoro-6-(3-pyrrolidin-1-ylpropoxy)-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

7-fluoro-8-[2-fluoro-6-[3-(1-piperidyl)propoxy]-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(azetidin-1-yl)propoxy]-2-fluoro-3-pyridyl]-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

15 8-[6-[3-(azetidin-1-yl)propoxy]-2-fluoro-3-pyridyl]-7-fluoro-1-isopropyl-3-methyl-imidazo[4,5-c]quinolin-2-one;

8-[6-[3-(Dimethylamino)propoxy]-3-pyridyl]-7-fluoro-1-isopropyl-3H-imidazo[4,5-c]quinolin-2-one; and

20 7-Fluoro-1-isopropyl-8-[6-[3-(1-piperidyl)propoxy]-3-pyridyl]-3H-imidazo[4,5-c]quinolin-2-one.

9. A pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, and at least one pharmaceutically acceptable excipient.

25

10. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, for use in therapy.

11. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, for use in the treatment of cancer.

30

12. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer according to claim 11, where the compound of Formula **(I)** is administered simultaneously, separately or sequentially with radiotherapy.
- 5 13. A compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer according to claim 11, where the compound of Formula **(I)** is administered simultaneously, separately or sequentially with at least one additional anti-tumour substance selected from the group consisting of doxorubicin, irinotecan, topotecan, etoposide, mitomycin, bendamustine, chlorambucil,
10 cyclophosphamide, ifosfamide, carmustine, melphalan and bleomycin.
14. Use of a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, in the manufacture of a medicament for the treatment of cancer.
- 15 15. A method for treating cancer in a warm-blooded animal in need of such treatment, which comprises administering to said warm-blooded animal a therapeutically effective amount of a compound of Formula **(I)**, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8.